Treace Medical Concepts (NASDAQ:TMCI) Upgraded to “Hold” at Wall Street Zen

Treace Medical Concepts (NASDAQ:TMCI) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Monday.

Other analysts also recently issued reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Treace Medical Concepts in a research note on Wednesday, January 21st. Stifel Nicolaus dropped their target price on Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating for the company in a report on Wednesday, January 7th. UBS Group reduced their target price on shares of Treace Medical Concepts from $6.50 to $5.85 and set a “neutral” rating for the company in a research report on Friday, November 7th. Truist Financial decreased their price target on shares of Treace Medical Concepts from $4.00 to $3.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating and issued a $5.00 price objective (down previously from $8.00) on shares of Treace Medical Concepts in a research note on Friday, November 7th. Four analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $4.21.

Treace Medical Concepts Trading Down 1.6%

Shares of TMCI stock opened at $1.89 on Monday. Treace Medical Concepts has a 12-month low of $1.81 and a 12-month high of $10.03. The company has a market capitalization of $120.43 million, a PE ratio of -2.36 and a beta of 0.74. The firm has a 50 day moving average price of $2.41 and a two-hundred day moving average price of $4.54. The company has a quick ratio of 2.36, a current ratio of 3.37 and a debt-to-equity ratio of 0.60.

Hedge Funds Weigh In On Treace Medical Concepts

Several hedge funds have recently bought and sold shares of TMCI. Graham Capital Management L.P. bought a new stake in shares of Treace Medical Concepts during the 4th quarter worth approximately $27,000. Osaic Holdings Inc. raised its position in Treace Medical Concepts by 328.3% during the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock valued at $28,000 after purchasing an additional 3,674 shares in the last quarter. HighTower Advisors LLC bought a new stake in Treace Medical Concepts during the fourth quarter worth $33,000. Balance Wealth LLC bought a new stake in Treace Medical Concepts during the fourth quarter worth $37,000. Finally, AXQ Capital LP acquired a new stake in shares of Treace Medical Concepts in the 4th quarter valued at $42,000. 84.08% of the stock is owned by institutional investors.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.